New drug ENX-104 tested in healthy volunteers for safety and brain activity
NCT ID NCT07253272
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed early-phase study gave a single oral dose of ENX-104 to 10 healthy volunteers to check its safety, how the body processes it, and how well it binds to D2/D3 receptors in the brain. The main goal was to track any side effects. Since this was a small, first-in-human study in healthy people, it does not test whether the drug works for any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ENX-104
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Parexel London EPCU
London, Middlesex, HA1 3UJ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults